Last reviewed · How we verify

NCT02674204: STOP

STOP Heart Disease in Breast Cancer Survivors Trial

Terminated Phase 2 Results posted Last updated 15 May 2019
What this trial tests

Phase 2 trial testing Atorvastatin in Breast Cancer in 2 participants. Terminated before completion.

Timeline
5 May 2016
Primary endpoint
25 May 2018
25 May 2018

Quick facts

Lead sponsorCedars-Sinai Medical Center
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment2
Start date5 May 2016
Primary completion25 May 2018
Estimated completion25 May 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, female only, with Breast Cancer or Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected over the 12-month intervention period and within 30 days of the last administration of the study drug.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Study Agent
Serious: 0/1 (0%)
Deaths: 0/1
Control
Serious: 1/1 (100%)
Deaths: 0/1

Serious adverse events (2 terms)

ReactionSystemStudy AgentControl
colitisGastrointestinal disorders
diarrheaGastrointestinal disorders
Other adverse events (22 terms — click to expand)

ReactionSystemStudy AgentControl
alanine aminotransferase increasedInvestigations
arthralgiaMusculoskeletal and connective tissue disorders
aspartate aminotransferase increasedInvestigations
myalgiaMusculoskeletal and connective tissue disorders
nauseaGastrointestinal disorders
pain in extremityMusculoskeletal and connective tissue disorders
insomniaPsychiatric disorders
dyspepsiaGastrointestinal disorders
vomitingGastrointestinal disorders
neuralgiaNervous system disorders
abdominal crampingGastrointestinal disorders
fatigueGeneral disorders
painGeneral disorders
hot flashesReproductive system and breast disorders
dizzinessNervous system disorders
mood changesPsychiatric disorders
upper respiratory tract infectionInfections and infestations
abdominal infectionInfections and infestations
vitamin D deficiencyGeneral disorders
osteoporosisMusculoskeletal and connective tissue disorders
somnolenceNervous system disorders
diarrheaGastrointestinal disorders

Most-reported serious reactions: colitis, diarrhea.

Data from ClinicalTrials.gov NCT02674204 adverse events section.

Sponsor's own description

The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment. Atorvastatin may reduce or eliminate the harmful effects of chemotherapy treatment to the heart tissue of breast cancer patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cardio-oncology: an overview on outpatient management and future developments.
    Teske AJ, Linschoten M, Kamphuis JAM, Naaktgeboren WR, et al · · 2018 · cited 29× · PMID 30141030 · DOI 10.1007/s12471-018-1148-7
  2. Protecting the heart in cancer therapy.
    Finet JE, Tang WHW. · · 2018 · cited 14× · PMID 30345014 · DOI 10.12688/f1000research.15190.1

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02674204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing